Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 17/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24267755 | 1.00 | OPRL1 (0.40) | OPRL1OPRM1OPRK1OPRD1PIK3CD | |
| SCHEMBL3421713 | 0.90 | PIK3CD (0.45) | PIK3CD | |
| SCHEMBL26170494 | 0.85 | OPRL1 (0.43) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL24267759 | 0.84 | OPRL1 (0.47) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL25046263 | 0.84 | OPRL1 (0.47) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL22175017 | 0.83 | KDM4E (0.42) | PIK3CD | |
| SCHEMBL21164490 | 0.82 | POLB (0.45) | PIK3CD | |
| SCHEMBL23732159 | 0.82 | PIK3CD (0.42) | PIK3CD | |
| SCHEMBL3262537 | 0.81 | PIK3CD (0.39) | OPRL1OPRM1OPRK1PIK3CD | |
| SCHEMBL13461316 | 0.81 | POLB (0.44) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | OPRL1 4762/4885OPRM1 4786/4885OPRK1 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.